China (Mainland)
Premiumsupplier 
Roscovitine, CAS NO.186692-46-6
- FOB Price: USD: 1.00-1.00 /Gram Get Latest Price
- Min.Order: 100 Gram
- Payment Terms: L/C
- Available Specifications:
≥98.0%(100-500)Gram≥98.0%(1000-5000)Gram
- Product Details
Keywords
- Roscovitine,
- 2-(R)-(1-ETHYL-2-HYDROXYETHYLAMINO)-6-BENZYLAMINO-9-ISOPROPYLPURINE;2-(1-ETHYL-2-HYDROXYETHYLAMINO)-6-BENZYLAMINO-9-ISOPROPYLPURINE;6-BENZYLAMINO-2-(R)-[(1-ETHYL)-2-HYDROXYETHYLAMINO]-9-ISOPROPYLPURIN
- 186692-46-6
Quick Details
- ProName: Roscovitine,
- CasNo: 186692-46-6
- Molecular Formula: C19H26N6O
- Appearance: white solid
- Application: CAS：186692-46-6； API intermediates;Ap...
- DeliveryTime: 3 months
- PackAge: 100g,500g,1kg,25kg/drum
- Port: shang hai
- ProductionCapacity: 1000 Gram/Week
- Purity: 98%
- Storage: Dry seal
- Transportation: shipping
- LimitNum: 100 Gram
- Moisture Content: ≤1%
- Impurity: ≤0.5%
Superiority
Details
Roscovitine (Seliciclib, CYC202) is a potent and selective CDK inhibitor for Cdc2, CDK2 and CDK5 with IC50 of 0.65 μM, 0.7 μM and 0.16 μM; shows little effect on CDK4/6.
IC50 Value: 0.65 μM(Cdc2); 0.7 μM(CDK2); 0.16 μM(CDK5)
Target: Cdc2/CDK2/CDK5
in vitro: Roscovitine displays high efficiency and high selectivity towards some cyclin-dependent kinases with IC50 of 0.65, 0.7, 0.7 and 0.16 μM for cdc2/cyclin B, cdk2/cyclin A, cdk2/cyclin E and cdk5/p53, respectively. [1] Roscovitine reversibly inhibits the prophaselmetaphase transition in the micromolar range of starfish oocytes and sea urchin embryos, inhibits in vitro M-phase-promoting factor activity and in vitro DNA synthesis in Xenopus egg extracts, and suppresses the proliferation of mammalian cell lines with an average IC50 of 16 μM. In mesangial cells, Roscovitine results in a dose-dependent reduction of CDK2 activity that at concentrations of 7.5, 12.5 and 25 mM, Roscovitine causes a 25, 50% and 100% decrease in CDK2 activity, respectively.
in vivo: Roscovitine, at a dose of 50 mg/kg, significantly inhibits growth of The Ewing's sarcoma family of tumors (ESFT) xenografts. Roscovitine enhances the antitumor effect of doxorubicin without increased toxicity with a mechanism that involves cell cycle arrest rather than apoptosis in nude mice bearing established MCF7 xenografts.